Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01

• Published in: PloS one Vol. 16; no. 7; p. e0254061
• Main Authors: Rose, Loreto V. T., Schulz, Angela M., Graham, Stuart L.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 15.07.2021; Public Library of Science (PLoS)
• Subjects: Adolescent; Atropine; Atropine - therapeutic use; Axial Length, Eye - drug effects; Biology and Life Sciences; Care and treatment; Child; Children; Clinical medicine; Compliance; Complications and side effects; Disease Progression; Drug dosages; Engineering and Technology; Equivalence; Female; Growth rate; Health sciences; Humans; Male; Medicine and Health Sciences; Myopia; Myopia - drug therapy; Myopia - pathology; Patient outcomes; Pediatrics; People and Places; Physical Sciences; Pretreatment; Prevention; Prospective Studies; Refraction; Refraction, Ocular - drug effects; Signal to noise ratio; Social Sciences; Australia
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0254061

Identifying axial length growth rate as an indicator of fast progression before initiating atropine 0.01% for myopia progression in children. From baseline, axial length growth over six months was measured prospectively. Subjects were then initiated on atropine 0.01% if axial length growth was greater than 0.1mm per 6 months (fast progressors), axial length and spherical equivalent change measurements recorded every six months. The rate of change was compared to the baseline pre-treatment rate. If axial length change was below the threshold, subjects received monitoring only. 73 subjects were identified as fast progressors and commenced atropine 0.01%, (mean baseline refraction of OD -2.9±1.6, OS -2.9±1.8 and a mean baseline axial length OD 24.62 ± 1.00 mm, OS 24.53 ± 0.99 mm). At six months, the mean paired difference of axial length growth rate was significantly reduced by 50% of baseline (all 73 subjects, p<0.05). 53 subjects followed to 12 months, and 12 to 24 months maintained a reduced growth rate. Change in mean spherical equivalent was significantly reduced compared to pre-treatment refractive error (mean paired difference p<0.05) and at each subsequent visit. 91 children were slow progressors and remained untreated. Their axial length growth rate did not change significantly out to 24 months. Spherical equivalent changed less than -0.5D annually in this group. Identifying fast progressors before treatment initiation demonstrated a strong treatment effect with atropine 0.01% reducing their individual rate of myopia progression by 50%. Another large group of myopic children, slow progressors, continued without medical intervention. A baseline axial length growth rate is proposed as a guideline to identify fast progressors who are more likely to benefit from atropine 0.01%.